Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model

Table 1 Clinical information of the training and validation cohorts, n (%)/mean ± SD

Characteristics	Training cohort (n = 85)	Validation cohort (n = 37)	P value
Sex			0.430
Male	73 (85.9)	33 (89.2)
Female	12 (14.1)	4 (10.8)
Age	54.35 ± 10.930	57.43 ± 10.219	0.147
Child-Pugh class			0.213
A	67 (78.8)	26 (70.3)
B	18 (21.2)	11 (29.7)
Hepatitis			0.040
None	4 (4.7)	1 (2.7)
Hepatitis B	79 (92.9)	32 (86.5)
Hepatitis C	1 (1.2)	1 (2.7)
Alcoholic hepatitis	1 (1.2)	3 (8.5)
PT (s)			0.458
≤ 14	80 (94.1)	34 (91.9)
> 14	5 (5.9)	3 (8.1)
TB (μmol/L)			0.173
≤ 17.1	41 (48.2)	22 (59.5)
> 17.1	44 (51.8)	15 (40.5)
ALB (g/L)			0.144
≤ 35	45 (52.9)	15 (40.5)
> 35	40 (47.1)	22 (59.5)
AST (U/L)			0.357
≤ 40	18 (21.2)	6 (16.2)
> 40	67 (78.8)	31 (83.8)
ALT (U/L)			0.194
≤ 50	59 (69.4)	22 (59.5)
> 50	26 (30.6)	15 (40.5)
AFP (ng/mL)			0.326
≤ 400	27 (31.8)	14 (37.8)
> 400	58 (68.2)	23 (62.2)

PT: Prothrombin time; TB: Total bilirubin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein.